Funding
Probe Scientific, which is developing a device called MicroEye for taking continuous blood samples without removing whole blood, has announced the completion of a £1 million funding round led by Catapult Venture Managers and supported by the National Endowment for Science Technology and the Arts (NESTA) and existing shareholders and directors.
Probe CEO Neil Smith said, “The funds will allow us to move forward quickly and to integrate our device with other ICU data and display systems. At the same time we will be able to develop new applications including opportunities in drug development, sports medicine and neonatal care.”
Probe’s first market for MicroEye is the critical care market for blood glucose measurement. The company says that its device will allow continuous glucose measurement in intensive care.
Receive the Funding Newswire [full access requires a subscription] each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
